Roquefort Therapeutics plc / Fundamentals
Income statement
- Net revenue
€233.58K - Cost of goods sold
€29.15K - Gross profit
€204.44K - SG&A expenses
€3.29M - R&D expenses
€1.14M - EBITDA
-€2.98M - D&A
€510.03K - EBIT
-€1.99M - Interest expenses
€0.00 - EBT
-€4.04M - Tax expenses
-€20.82K - Net income
-€3.66M
Cash flow statement
- Net deferred tax
-€2.09M - Non-cash items
€1.88M - Changes in working capital
-€2.09M - Operating cash flow
-€6.04M - Capex
€62.28K - Other investing cash flow
€1.92K - Net investing cash flow
-€179.60K - Total cash dividends paid
€0.00 - Issuance of common stock
€3.75M - Debt repayment
€0.00 - Other financing cash flow
€3.08M - Net financing cash flow
€3.08M - Foreign exchange effects
-€6.88K - Net change in cash
-€3.15M - Cash at end of period
€686.40K - Free cash flow
-€5.97M
Balance sheet
- Cash and cash equivalents
€686.40K - Cash and short-term investments
€686.40K - Total receivables
€100.67K - Inventory
€0.00 - Other current assets
€0.00 - Total current assets
€787.07K - Property, plant & equipment
€54.68K - Goodwill
€0.00 - Intangible assets
€6.16M - Long-term investments
€0.00 - Other non-current assets
€0.00 - Total non-current assets
€6.21M - Total assets
€7.00M - Accounts payable
€156.29K - Short-term debt
€702.58K - Other current liabilities
€135.32K - Total current liabilities
€994.19K - Long-term debt
€0.00 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€324.86K - Total liabilities
€1.32M - Common stock
€1.49M - Retained earnings
-€1.35M - Other equity
€4.73M - Total equity
€5.68M - Total liabilities and shareholders' equity
€7.00M
Company information
- Market capitalization
€2.26M - Employees
7 - Enterprise Value
€2.31M
Company ratios
- Gross margin
-
87.5% Much better than peer group: -10,667.9% - EBITDA margin
-
-1,275.9% Much worse than peer group: 1,293.5% - EBIT margin
-
-853.1% Much better than peer group: -46,615.2% - EBT margin
-
-1,730.1% Much worse than peer group: 69,327.3% - Net margin
-
-1,567.4% Much worse than peer group: 45,773.7% - ROE
-
-64.5% Much worse than peer group: 236.0% - ROA
-
-52.3% Much better than peer group: -21,869.9% - Asset turnover
-
3.3% Much worse than peer group: 312.4% - FCF margin
-
-2,610.5% Much better than peer group: -35,055.3% - FCF yield
-270.0% - Efficiency ratio
1,375.9% - Net sales per employee
-
€33.37K - Net income per employee
-
-€523.03K